Kornitzer Capital Management Inc. KS Purchases 21,164 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Kornitzer Capital Management Inc. KS lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1,058.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,164 shares of the biopharmaceutical company’s stock after buying an additional 21,164 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Alnylam Pharmaceuticals were worth $7,554,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of ALNY. SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the first quarter worth $27,000. Bessemer Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $42,000. AlphaQuest LLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at $43,000. Finally, Washington Trust Advisors Inc. raised its stake in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.1%

NASDAQ ALNY opened at $463.43 on Friday. The company’s 50-day moving average price is $459.27 and its 200-day moving average price is $360.97. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock has a market cap of $60.75 billion, a PE ratio of -187.62 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Michael W. Bonney sold 11,250 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the transaction, the director directly owned 16,804 shares in the company, valued at approximately $7,561,800. This represents a 40.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director owned 775 shares in the company, valued at approximately $362,390. The trade was a 95.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 98,144 shares of company stock valued at $44,160,261. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research note on Monday, October 6th. BMO Capital Markets boosted their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Stifel Nicolaus boosted their price objective on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a “buy” rating in a research report on Monday, October 6th. Finally, Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research report on Monday, August 4th. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $466.92.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.